- Champignon Brands Appoints Jay Kheita to the Company’s Special Advisory Committee
- Mr. Kheita is a Founder of AltMed Capital Corp, a Leading Canadian Psychedelic Medicine Clinic Operator
- Since Last Week’s Technical Breakout Alert, Shares of SHRM Have Surged as Much as 77%
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496) announced on Tuesday that it appointed another essential member to its Special Advisory Committee. Champignon reported that Mr. Jay Kheita, ACPR, has joined the team and will help lead the integration of the company’s novel and natural treatment protocols into its existing consumer packaged goods (CPG) portfolio.
Champignon Brands is a leading human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine. The company continues to bolster its Special Advisory Committee by adding critical individuals with experience operating in highly regulated growth sectors such as the Psychedelics industry.
Champignon’s Special Advisory Committee continues to evaluate the potential positive effects of its novel and natural treatment protocols and ongoing preclinical trials on individuals suffering from indications such as depression, post-traumatic stress disorder (PTSD), traumatic brain injuries (TBI), obsessive-compulsive disorder (OCD), as well as substance and alcohol use disorders.
Mr. Khetia holds pharmacy licences in Canada, Australia and England and is a graduate of the University of Brighton, where he achieved an honours degree in pharmacy specializing in pharmacognosy, the study of medicinal plants. Khetia is also a founder of AltMed Capital Corp., a leading Canadian psychedelic medicine clinic operator, IP aggregator and solutions provider, and is currently a clinical advisor at the Leslie Dan Faculty of Pharmacy at the University of Toronto.
Khetia strongly believes that alternative health innovations have the potential to treat patients for various chronic diseases, including PTSD, depression and anxiety, thus creating a strong synergy with Champignon’s ongoing psychedelic medicine focused studies and preclinical activities.
“We are pleased to welcome Jay to Champignon’s Special Advisory Committee, where he will function as a cornerstone advisor throughout our pursuit to develop and deploy precision medicine focused formulations and delivery systems,” stated Gareth Birdsall, CEO of Champignon Brands.
SHRM Price Action and Chart Update
As we first reported on March 25, 2020, shares of Champignon Brands’ CSE listed SHRM stock recently experienced a strong breakout from its bull pennant chart formation. Since bull pennants are continuation patterns, we informed our readers that it was highly likely that SHRM would continue its upward trajectory.
We are pleased to report that following last week’s SHRM technical breakout article, the stock has continued to rise as anticipated. Since closing at $0.35 on the day of its breakout (March 25, 2020), SHRM has soared as much as 77.14% while reaching a high of $0.62 per share. As of Tuesday’s closing price of $0.59, SHRM is up over 68.5% since our technical breakout alert. For those that paid attention, congrats to you.
The psychedelics sector has emerged as a new high growth opportunity for investors. There is now significant investor demand, but few publicly traded companies in the space. As a result, demand is being concentrated into industry-leading names such as Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496) and MindMed (NEO: MMED) (OTC: MMEDF) (FRA: BGHM). Shares of both stocks skyrocketed over the past week as the word continues to spread throughout the investing community.
The psychedelics sector is in its infancy and will likely follow a similar path as the early days of the cannabis boom. Remember, the trend is your friend, and because we’re so early in the game, the psychedelics uptrend has likely only begun.
SHRM Chart from Our March 25, 2020, Technical Alert Article:
SHRM Chart, March 31, 2020:
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.